| 1 |
34069389 | 17-AAG-Induced Activation of the Autophagic Pathway in Leishmania Is Associated with Parasite Death. | 2021 May 19 |
1 |
| 2 |
32527461 | Enzymatic biosynthesis and biological evaluation of novel 17-AAG glucoside as potential anti-cancer agents. | 2020 Aug 1 |
1 |
| 3 |
32585150 | Solid lipid nanoparticles as a novel formulation approach for tanespimycin (17-AAG) against leishmania infections: Preparation, characterization and macrophage uptake. | 2020 Nov |
3 |
| 4 |
30982499 | Nonsteroidal Anti-inflammatory Drugs Sensitize CD44-Overexpressing Cancer Cells to Hsp90 Inhibitor Through Autophagy Activation. | 2019 Jul 12 |
1 |
| 5 |
29297949 | Effect of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on Akt protein expression is more effective in head and neck cancer cell lineages that retain PTEN protein expression. | 2018 Mar |
1 |
| 6 |
29317342 | Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. | 2018 Apr |
1 |
| 7 |
29676157 | A High-Throughput Assay for Collagen Secretion Suggests an Unanticipated Role for Hsp90 in Collagen Production. | 2018 May 15 |
1 |
| 8 |
29800308 | Heat shock protein 90α couples with the MAPK-signaling pathway to determine meiotic maturation of porcine oocytes. | 2018 Jul 28 |
1 |
| 9 |
29953987 | 17-(Allylamino)-17-Demethoxygeldanamycin Enhances Etoposide-Induced Cytotoxicity via the Downregulation of Xeroderma Pigmentosum Complementation Group C Expression in Human Lung Squamous Cell Carcinoma Cells. | 2018 |
1 |
| 10 |
30378153 | 17-allylamino-17-demethoxygeldanamycin impeded chemotherapy through antioxidant activation via reducing reactive oxygen species-induced cell death. | 2018 Oct 30 |
1 |
| 11 |
28239659 | Hsp90 regulation of fibroblast activation in pulmonary fibrosis. | 2017 Feb 23 |
1 |
| 12 |
28336809 | Lectin, Galactoside-Binding Soluble 3 Binding Protein Promotes 17-N-Allylamino-17-demethoxygeldanamycin Resistance through PI3K/Akt Pathway in Lung Cancer Cell Line. | 2017 Jul |
1 |
| 13 |
28789442 | Effects of 17-allylamino-17-demethoxygeldanamycin on the induction of apoptosis and cell cycle arrest in HCT-116 cells. | 2017 Aug |
1 |
| 14 |
27075590 | HSP90 Inhibition Suppresses PGE2 Production via Modulating COX-2 and 15-PGDH Expression in HT-29 Colorectal Cancer Cells. | 2016 Jun |
1 |
| 15 |
27279418 | Effects of 17-AAG on the cell cycle and apoptosis of H446 cells and the associated mechanisms. | 2016 Aug |
1 |
| 16 |
27894402 | HSP90 inhibitor enhances anti-proliferative and apoptotic effects of celecoxib on HT-29 colorectal cancer cells via increasing BAX/BCL-2 ratio. | 2016 Oct 31 |
1 |
| 17 |
24277352 | Up-regulation of Gadd45α after exposure to metal nanoparticles: the role of hypoxia inducible factor 1α. | 2015 Apr |
1 |
| 18 |
24623685 | DNA aneuploidy-specific therapy for head and neck squamous cell carcinoma. | 2015 Jun |
1 |
| 19 |
26268232 | [Effects of 17-AAG on the proliferation and apoptosis of human lung cancer A549 and H446 cells]. | 2015 Apr |
1 |
| 20 |
26313837 | Heat Shock Protein 90 Inhibitor Decreases Collagen Synthesis of Keloid Fibroblasts and Attenuates the Extracellular Matrix on the Keloid Spheroid Model. | 2015 Sep |
1 |
| 21 |
26501082 | Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells. | 2015 |
1 |
| 22 |
24166505 | HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. | 2014 Oct 2 |
1 |
| 23 |
24303801 | Novel mechanism of attenuation of LPS-induced NF-κB activation by the heat shock protein 90 inhibitor, 17-N-allylamino-17-demethoxygeldanamycin, in human lung microvascular endothelial cells. | 2014 May |
1 |
| 24 |
24317439 | The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway. | 2014 Feb |
2 |
| 25 |
24718854 | Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer. | 2014 Jun |
1 |
| 26 |
24798692 | Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. | 2014 May 15 |
1 |
| 27 |
24879994 | SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG. | 2014 Jul 18 |
1 |
| 28 |
24886060 | Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG. | 2014 May 15 |
1 |
| 29 |
25227799 | Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer. | 2014 |
1 |
| 30 |
22955701 | The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells. | 2013 Nov |
1 |
| 31 |
23229511 | Aryl hydrocarbon receptor is a target of 17-Allylamino-17-demethoxygeldanamycin and enhances its anticancer activity in lung adenocarcinoma cells. | 2013 Mar |
1 |
| 32 |
23564374 | Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. | 2013 May |
1 |
| 33 |
23629654 | Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation. | 2013 Jun 14 |
2 |
| 34 |
23886587 | The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition. | 2013 Nov |
2 |
| 35 |
24012704 | Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme. | 2013 Dec 1 |
1 |
| 36 |
24185264 | Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX. | 2013 Nov |
1 |
| 37 |
20683637 | A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. | 2012 Feb |
1 |
| 38 |
21830942 | Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines. | 2012 Jan |
1 |
| 39 |
22099584 | Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG. | 2012 Jul |
1 |
| 40 |
22377218 | Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer. | 2012 Jun 1 |
2 |
| 41 |
22566604 | Inhibition of the mTORC2 and chaperone pathways to treat leukemia. | 2012 Jun 21 |
1 |
| 42 |
22621282 | Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy. | 2012 May 23 |
1 |
| 43 |
22687408 | The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells. | 2012 |
1 |
| 44 |
22711259 | 17-allylamino-17-(demethoxy)geldanamycin (17-AAG) is a potent and effective inhibitor of human cytomegalovirus replication in primary fibroblast cells. | 2012 Oct |
2 |
| 45 |
23650580 | The Hsp90 inhibitor 17-AAG represses calcium-induced cytokeratin 1 and 10 expression in HaCaT keratinocytes. | 2012 |
1 |
| 46 |
20816782 | 17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy. | 2011 Jan |
1 |
| 47 |
21517103 | Nano self-assembly of recombinant human gelatin conjugated with α-tocopheryl succinate for Hsp90 inhibitor, 17-AAG, delivery. | 2011 May 24 |
1 |
| 48 |
21542685 | Synergistic administration of photothermal therapy and chemotherapy to cancer cells using polypeptide-based degradable plasmonic matrices. | 2011 Apr |
1 |
| 49 |
21558407 | HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. | 2011 Aug 1 |
2 |
| 50 |
21820041 | Multi-drug delivery to tumor cells via micellar nanocarriers. | 2011 Oct 31 |
1 |